MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters

Journal of the Society for Gynecologic Investigation

Volumn 10, Issue 7, 2003, Pages 443-446

  Bodner Adler, Barbara ^a   Bodner, K ^a   Kimberger, O ^a   Czerwenka, K ^a   Leodolter, S ^a   Mayerhofer, K ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinicopathologic parameters; MMP 1 and MMP 2 expression; Uterine leiomyosarcoma

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE SECTION; UTERUS MYOMA; VASCULAR DISEASE;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 0141745540     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(03)00120-5     Document Type: Article

References (31)

1. Zaloudek C.J., Norris H.J. Mesenchymal tumors of the uterus. Kurman R.J. Blaustein's pathology of the female genital tract. 1994;849-914 Springer-Verlag, New York.
2. Evans H.L., Chawla S.P., Simpson C., Finn K.P. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer. 62:1988;2239-2247.
3. Nordal R.R., Kristensen G.B., Kaern J., Stenwig A.E., Pettersen E.O., Trope C.G. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 34:1995;797-802.
4. Van Dinh T., Woodruff J.O. Leiomyosarcoma of the uterus. Am J Obstet Gynecol. 144:1982;817-823.
5. Silverberg S.G. Leiomyosarcoma of the uterus. A clinicopathologic study. Obstet Gynecol. 38:1971;613-628.
6. Henderson S., Rowe M., Gregory C., et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 67:1991;1107-1115.
7. Brummer O., Böhmer G., Hollwitz B., Flemming P., Petry K., Kühnle H. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study. Gynecol Oncol. 84:2002;222-227.
8. Cox G., O'Byrne K.J. Matrix metalloproteinases and cancer. Anticancer Res. 21:2001;4207-4220.
9. Huppertz B., Kerschanska S., Demir A.Y., Frank H.G., Kaufmann P. Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res. 291:1998;133-148.
10. Bishof P., Haenggli L., Campana A. Gelatinase and oncofetal fibronectin expression is dependent on integrin expression on human cytotrophoblasts. Hum Reprod. 10:1995;734-742.
11. Stetler-Stevenson W.G. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 148:1996;1345-1350.
12. Jones J.L., Walker R.A. Control of matrix metalloproteinase activity in cancer. J Pathol. 183:1997;377-379.
13. Kikkawa F., Nawa A., Shibata N., et al. The different stimulatory effect of normal tissues on the secretion of matrix metalloproteinases and their inhibitors by human ovarian cancer cells. Anticancer Res. 18:1998;4323-4328.
14. Vegh G.L., Tuncer Z.S., Fulop V., Genest D.R., Mok S.C., Berkowitz R.S. Matrix metalloproteinases and their inhibitors in gestational trophoblastic disease and normal placenta. Gynecol Oncol. 75:1999;248-253.
15. Nouvo G.J., MacConnel P.B., Simsir A., Valea F., French D.L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complentary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55:1995;267-275.
16. Sier C.F., Merino M.J., San-Juan J., Liotta L.A., Stetler-Stevenson W.G. Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol. 136:1990;585-592.
17. Shima I., Sagaguri Y., Kusukawa J., et al. Production of matrix metalloproteinase -2 metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 70:1992;2747-2753.
18. Bell S.W., Kempson R.L., Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 18:(6):1994;535-558.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
20. Tokuraku M., Sato H., Murakami S., Okada Y., Watanabe Y., Seiki M. Activation of the precursor of gelatinase A/72kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT1-MMP) and with lymph node metastasis. Int J Cancer. 64:1995;355-359.
21. Vaisanen A., Tuominen H., Kallioinen M., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72kD type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J Pathol. 180:1996;283-289.
22. Djonov V., Cresto N., Aebersold D.M., et al. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Cancer. 21:(1):2002;25-30.
23. Herbst H., Wege T., Milani S., et al. Tissue inhibitor of metalloproteinases-1 and-2 expression in rat and human liver fibrosis. Am J Pathol. 150:1997;1647-1659.
24. Huhtala P., Chow L.T., Tryggvason K. Structure of human type IV collagenase gene. J Biol Chem. 265:1990;11077-11082.
25. Tanimoto H., Shigemasa K., Sasaki M., et al. Differential expression of matrix metalloproteinase-7 in each component of uterine carcinosarcoma. Oncol Rep. 7:(6):2000;1209-1212.
26. Liokumovich P., Goldberg I., Davidson B., et al. Expression of metalloproteinases endometrial stromal sarcoma Immunohistochemical study using image analysis . J Clin Pathol. 52:1999;198-202.
27. Mayerhofer K., Obermair A., Windbichler G., et al. Leiomyosarcoma of the uterus A clinicopathologic multicenter study of 71 cases . Gynecol Oncol. 74:(2):1999;196-201.
28. Johnson M.D., Kim H.R.C., Chesler L., Tsao-Wu G., Bouck N., Polverini P.J. Inhibition of angiogenesis by tissue inhibitor of metalloproteinases. J Cell Physiol. 160:1994;194-202.
29. Vardi J.R., Tovell H.M.M. Leiomyosarcoma of the uterus Clinicopathologic study . Obstet Gynecol. 56:1980;428-434.
30. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9:1990;289-303.
31. Zucker S., Lysik R.M., Zarrabi M.H., Moll U. M(r) 92,000type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53:1993;140-146.